• Loading stock data...
Est. 2004

Wednesday 03/6/2019

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

clinical trial

  • 5:55 PM

    Median survival of top 100 patients is 40.5 months,Median survival of all 331 patients is 23.1 months, Longest survivors have exceeded 7 years BETHESDA, Md., May 29, 2018 /PRNewswire-USNewswire/ — Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.  The data were collected by the independent contract research

    Read more
  • 12:05 PM

    NEW YORK, March 21, 2017, AXIM, (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has retained the services of Ora®, Inc., a global Contract Research Organization (“CRO”), to perform the company’s upcoming product development (based on AXIM’s IP) and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. Ora is the world’s leading ophthalmology CRO for advancing products from pre-clinical through approval and post-market phases.

    Read more
  • 11:41 AM

    BATON ROUGE, LA– OBMP, (Marketwired – December 12, 2016) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the European Patent Office has approved the Company’s patent application number 12701292.0 protecting ProscaVax as a PSA (prostate specific antigen) cancer vaccine. The patent is broad in scope covering an array of therapeutic cancer vaccine compositions built upon OncBioMune’s protein

    Read more
  • 4:36 PM

    These images show a tumor that is being targeted with a new drug called 89Zr-DFO-5B1, which is designed to detect CA19.9, a protein that is elevated in more than 90% of pancreatic tumors as well as in some other cancers. Memorial Sloan Kettering was recently given permission from the FDA to conduct the first-ever clinical trial with this new drug in patients with pancreatic cancer. The left panel shows a thin slice of the tumor that has been stained with

    Read more
  • 6:17 PM

    LOS ANGELES, Feb. 23, 2016 /PRNewswire/ — Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA] announced today that inventors of OXS-1550 received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of various human cancers. “We are pleased the USPTO has agreed that OXS-1550 is a patentable therapeutic composition. This is

    Read more
  • 3:44 PM

    NEW YORK, Feb. 10, 2016, DCTH, /PRNewswire/ — Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that patient enrollment has begun in the Company’s Phase 3 clinical trial:  “A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma” (the FOCUS Trial). The first patient was evaluated and randomized into

    Read more
Public Wire Banner